{"nctId":"NCT02846532","briefTitle":"Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure","startDateStruct":{"date":"2016-11-16","type":"ACTUAL"},"conditions":["Thrombosis"],"count":112,"armGroups":[{"label":"Rivaroxaban","type":"EXPERIMENTAL","interventionNames":["Drug: Rivaroxaban"]},{"label":"Acetylsalicylic Acid","type":"EXPERIMENTAL","interventionNames":["Drug: Acetylsalicylic Acid"]}],"interventions":[{"name":"Rivaroxaban","otherNames":[]},{"name":"Acetylsalicylic Acid","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant must be considered to be clinically stable by the investigator and able to tolerate oral or enteral administration of a suspension formulation and oral/enteral feedings\n* Satisfactory initial post-Fontan transthoracic echocardiographic Screening as defined in the Post-Fontan Echocardiographic Examination Research Protocol\n* Parent/legally acceptable representative must sign an informed consent form (ICF) and child assent will also be provided, if applicable, according to local requirements\n\nExclusion Criteria:\n\n* Evidence of thrombosis, including those that are asymptomatic confirmed by post-Fontan procedure transthoracic echocardiogram, or other imaging techniques, during the Screening period of the study\n* History of gastrointestinal disease or surgery associated with clinically relevant impaired absorption\n* History of or signs/symptoms suggestive of protein-losing enteropathy\n* Active bleeding or high risk for bleeding contraindicating antiplatelet or anticoagulant therapy, including a history of intracranial bleeding\n* Platelet count less than (\\<)50\\*10\\^9/Liters (L) at Screening\n* Estimated glomerular filtration rate (eGFR) \\<30 milliliters per minute per 1.73 meter square (mL/min/1.73m\\^2)\n* Known clinically significant liver disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"8 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Any Thrombotic Event (Venous or Arterial and Symptomatic or Asymptomatic)","description":"Thrombotic event was defined as the appearance of a new thrombotic burden within the cardiovascular system on either routine surveillance or clinically indicated imaging, or the occurrence of a clinical event known to be strongly associated with thrombus (such as cardioembolic stroke, pulmonary embolism). The event included ischemic stroke, pulmonary embolism, venous thrombosis, arterial/intracardiac thrombosis, and other thrombosis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"1.6","spread":null},{"groupId":"OG002","value":"8.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.6","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Plasma Concentration of Rivaroxaban at Day 1 (0.5-1.5 Hours Postdose)","description":"Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.69","spread":"39.4"},{"groupId":"OG001","value":"92.86","spread":"72.6"}]}]}]},{"type":"PRIMARY","title":"Plasma Concentration of Rivaroxaban at Day 1 (1.5-4 Hours Postdose)","description":"Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.62","spread":"43.1"},{"groupId":"OG001","value":"103.61","spread":"62.6"}]}]}]},{"type":"PRIMARY","title":"Plasma Concentration of Rivaroxaban at Day 4 (Up to 3 Hours Predose)","description":"Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.58","spread":"37.4"}]}]}]},{"type":"PRIMARY","title":"Plasma Concentration of Rivaroxaban at Day 4 (0.5-1.5 Hours Postdose)","description":"Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107.58","spread":"54.2"}]}]}]},{"type":"PRIMARY","title":"Plasma Concentration of Rivaroxaban at Day 4 (1.5-4 Hours Postdose)","description":"Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147.18","spread":"116"}]}]}]},{"type":"PRIMARY","title":"Plasma Concentration of Rivaroxaban at Day 4 (6-8 Hours Postdose)","description":"Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.81","spread":"64.6"}]}]}]},{"type":"PRIMARY","title":"Plasma Concentration of Rivaroxaban at Month 3 (Up to 3 Hours Predose)","description":"Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.23","spread":"25.7"},{"groupId":"OG001","value":"29.41","spread":"25.5"}]}]}]},{"type":"PRIMARY","title":"Plasma Concentration of Rivaroxaban at Month 3 (0.5-1.5 Hours Postdose)","description":"Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.25","spread":"32.0"},{"groupId":"OG001","value":"94.12","spread":"82.2"}]}]}]},{"type":"PRIMARY","title":"Plasma Concentration of Rivaroxaban at Month 3 (2.5-4 Hours Postdose)","description":"Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.67","spread":"58.4"},{"groupId":"OG001","value":"102.99","spread":"56.0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Bleeding Events","description":"Bleeding events were categorized into major, clinically relevant non-major bleeding (CRNM), and trivial bleeding events. Major bleeding: overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more; or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults; or occurring in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; or contributing to death. CRNM bleeding: overt bleeding not meeting the criteria for major bleeding but associated with: Medical intervention, or Unscheduled contact with a physician, cessation of study treatment, or Discomfort for the subject such as pain, or Impairment of activities of daily life. Trivial bleeding: any other overt bleeding event that does not meet criteria for CRNM bleeding.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"35.9","spread":null},{"groupId":"OG002","value":"41.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.6","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"6.3","spread":null},{"groupId":"OG002","value":"8.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"32.8","spread":null},{"groupId":"OG002","value":"35.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Absolute Prothrombin Time (PT) at Day 1 (0.5-1.5 Hours Postdose)","description":"Absolute prothrombin time was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.46","spread":"1.90"},{"groupId":"OG001","value":"18.02","spread":"2.58"}]}]}]},{"type":"PRIMARY","title":"Absolute PT at Day 1 (1.5-4 Hours Postdose)","description":"Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.58","spread":"1.84"},{"groupId":"OG001","value":"18.76","spread":"2.25"}]}]}]},{"type":"PRIMARY","title":"Absolute PT at Day 4 (Up to 3 Hours Predose)","description":"Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.21","spread":"1.54"}]}]}]},{"type":"PRIMARY","title":"Absolute PT at Day 4 (0.5-1.5 Hours Postdose)","description":"Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.95","spread":"2.10"}]}]}]},{"type":"PRIMARY","title":"Absolute PT at Day 4 (1.5-4 Hours Postdose)","description":"Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.73","spread":"3.30"}]}]}]},{"type":"PRIMARY","title":"Absolute PT at Day 4 (6-8 Hours Postdose)","description":"Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.13","spread":"2.13"}]}]}]},{"type":"PRIMARY","title":"Absolute PT at Month 3 (Up to 3 Hours Predose)","description":"Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.59","spread":"2.65"},{"groupId":"OG001","value":"16.45","spread":"2.27"}]}]}]},{"type":"PRIMARY","title":"Absolute PT at Month 3 (0.5-1.5 Hours Postdose)","description":"Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.13","spread":"3.55"},{"groupId":"OG001","value":"18.89","spread":"3.69"}]}]}]},{"type":"PRIMARY","title":"Absolute PT at Month 3 (2.5-4 Hours Postdose)","description":"Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.14","spread":"2.61"},{"groupId":"OG001","value":"19.69","spread":"2.81"}]}]}]},{"type":"PRIMARY","title":"Activated Partial Thromboplastin Time (aPTT) at Day 1 (0.5-1.5 Hours Postdose)","description":"aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.4","spread":"4.68"},{"groupId":"OG001","value":"30.69","spread":"8.23"}]}]}]},{"type":"PRIMARY","title":"aPTT at Day 1 (1.5-4 Hours Postdose)","description":"aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.83","spread":"3.79"},{"groupId":"OG001","value":"30.25","spread":"3.80"}]}]}]},{"type":"PRIMARY","title":"aPTT at Day 4 (Up to 3 Hours Predose)","description":"aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.08","spread":"5.68"}]}]}]},{"type":"PRIMARY","title":"aPTT at Day 4 (0.5-1.5 Hours Postdose)","description":"aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.17","spread":"6.99"}]}]}]},{"type":"PRIMARY","title":"aPTT at Day 4 (1.5-4 Hours Postdose)","description":"aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average for the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.58","spread":"8.45"}]}]}]},{"type":"PRIMARY","title":"aPTT at Day 4 (6-8 Hours Postdose)","description":"aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.83","spread":"5.94"}]}]}]},{"type":"PRIMARY","title":"aPTT at Month 3 (Up to 3 Hours Predose)","description":"aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.36","spread":"3.76"},{"groupId":"OG001","value":"28.70","spread":"3.76"}]}]}]},{"type":"PRIMARY","title":"aPTT at Month 3 (0.5-1.5 Hours Postdose)","description":"aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.60","spread":"2.55"},{"groupId":"OG001","value":"31.15","spread":"4.17"}]}]}]},{"type":"PRIMARY","title":"aPTT at Month 3 (2.5-4 Hours Postdose)","description":"aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.74","spread":"1.79"},{"groupId":"OG001","value":"31.67","spread":"3.58"}]}]}]},{"type":"PRIMARY","title":"Anti-FXa at Day 1 (0.5-1.5 Hours Postdose)","description":"Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.93","spread":"23.9"},{"groupId":"OG001","value":"99.46","spread":"60.6"}]}]}]},{"type":"PRIMARY","title":"Anti-FXa at Day 1 (1.5-4 Hours Postdose)","description":"Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.06","spread":"32.4"},{"groupId":"OG001","value":"104.57","spread":"55.5"}]}]}]},{"type":"PRIMARY","title":"Anti-FXa at Day 4 (6-8 Hours Postdose)","description":"Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.21","spread":"60.6"}]}]}]},{"type":"PRIMARY","title":"Anti-FXa at Month 3 (Up to 3 Hours Predose)","description":"Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.51","spread":"29.4"},{"groupId":"OG001","value":"53.41","spread":"15.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)","description":"TEAEs were defined as those adverse events (AEs) that occurred from the first day of study drug to the last day of study drug + 2 days inclusive. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"85.9","spread":null},{"groupId":"OG002","value":"85.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-FXa at Month 3 (0.5-1.5 Hours Postdose)","description":"Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"110.90","spread":"75.8"}]}]}]},{"type":"PRIMARY","title":"Anti-FXa at Month 3 (2.5-4 Hours Postdose)","description":"Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"93.48","spread":"50.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":12},"commonTop":["Pyrexia","Nasopharyngitis","Upper Respiratory Tract Infection","Cough","Vomiting"]}}}